Staar Compliance Effort Exempt From Belt Tightening; Merger Among Options
This article was originally published in The Gray Sheet
Executive Summary
Staar Surgical will seek to raise $8 mil.-$10 mil. from existing investors to shore up its cash position while it considers strategic alternatives, including a possible sale of the company, the firm says
You may also be interested in...
Staar Prepares For Visian ICL Launch Following Long-Awaited FDA Approval
Staar Surgical will target the three million U.S. patients with severe myopia as it rolls out its Visian ICL implantable contact lens after announcing long-awaited PMA approval Dec. 23
Staar Prepares For Visian ICL Launch Following Long-Awaited FDA Approval
Staar Surgical will target the three million U.S. patients with severe myopia as it rolls out its Visian ICL implantable contact lens after announcing long-awaited PMA approval Dec. 23
Staar Will Respond To FDA On “Serious, Continuing Violations”
Staar Surgical said it would issue a report to FDA July 15 detailing the firm's plans for resolving a series of quality systems violations